Cyclophosphamide-induced atrial fibrillation in the context of ANCA-associated vasculitis: a case report.

IF 1.7 Q2 MEDICINE, GENERAL & INTERNAL
Annals of Medicine and Surgery Pub Date : 2025-01-09 eCollection Date: 2025-01-01 DOI:10.1097/MS9.0000000000002809
Sakar Pandey, Aayusha Dhakal, Roshan Singh, Rahul Shakya, Sweta Dhakal, Sagar Bhandari
{"title":"Cyclophosphamide-induced atrial fibrillation in the context of ANCA-associated vasculitis: a case report.","authors":"Sakar Pandey, Aayusha Dhakal, Roshan Singh, Rahul Shakya, Sweta Dhakal, Sagar Bhandari","doi":"10.1097/MS9.0000000000002809","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and importance: </strong>Cyclophosphamide is a widely used immunosuppressant for inducing remission in various immune-mediated conditions. However, its potential for cardiotoxicity is well documented. One of the earliest possible manifestations of this cardiotoxicity following cyclophosphamide infusion is atrial fibrillation (AF), which typically presents within 48 h of the infusion.</p><p><strong>Case presentation: </strong>The authors present a case of a 58-year-old male with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis who presented to the emergency department with clinical features of acute kidney injury. Following subsequent assessment and evaluation, the patient was managed in the intensive care unit with hemodialysis and intravenous corticosteroids. He was aimed at inducing remission with cyclophosphamide infusion. However, a few hours following induction with cyclophosphamide infusion, the patient developed palpitation, sweating, and tachycardia with a heart rate of 140-180/min. The electrocardiogram showed an irregular QRS complex with an absent p-wave. AF was diagnosed and managed with amiodarone infusion for 24 h followed by oral maintenance dosing. No further episode of AF occurred following cessation of cyclophosphamide and switching to rituximab for the treatment of ANCA-associated vasculitis.</p><p><strong>Clinical discussion: </strong>Cyclophosphamide, even at lower dosages, can cause cardiotoxicity in patients with renal impairment due to the delayed elimination of its toxic metabolites. In addition, patients who receive CYP 450 inducers, such as prednisone, may experience the accelerated build-up of its toxic metabolites, thereby raising the risk for cardiotoxicity.</p><p><strong>Conclusion: </strong>The cardiotoxic manifestation of cyclophosphamide can arise from its use in several immune-mediated conditions. Given its potential for cardiotoxicity, careful cardiac monitoring during and after cyclophosphamide infusion is essential to ensure timely intervention, if needed.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"87 1","pages":"376-379"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918588/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine and Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MS9.0000000000002809","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and importance: Cyclophosphamide is a widely used immunosuppressant for inducing remission in various immune-mediated conditions. However, its potential for cardiotoxicity is well documented. One of the earliest possible manifestations of this cardiotoxicity following cyclophosphamide infusion is atrial fibrillation (AF), which typically presents within 48 h of the infusion.

Case presentation: The authors present a case of a 58-year-old male with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis who presented to the emergency department with clinical features of acute kidney injury. Following subsequent assessment and evaluation, the patient was managed in the intensive care unit with hemodialysis and intravenous corticosteroids. He was aimed at inducing remission with cyclophosphamide infusion. However, a few hours following induction with cyclophosphamide infusion, the patient developed palpitation, sweating, and tachycardia with a heart rate of 140-180/min. The electrocardiogram showed an irregular QRS complex with an absent p-wave. AF was diagnosed and managed with amiodarone infusion for 24 h followed by oral maintenance dosing. No further episode of AF occurred following cessation of cyclophosphamide and switching to rituximab for the treatment of ANCA-associated vasculitis.

Clinical discussion: Cyclophosphamide, even at lower dosages, can cause cardiotoxicity in patients with renal impairment due to the delayed elimination of its toxic metabolites. In addition, patients who receive CYP 450 inducers, such as prednisone, may experience the accelerated build-up of its toxic metabolites, thereby raising the risk for cardiotoxicity.

Conclusion: The cardiotoxic manifestation of cyclophosphamide can arise from its use in several immune-mediated conditions. Given its potential for cardiotoxicity, careful cardiac monitoring during and after cyclophosphamide infusion is essential to ensure timely intervention, if needed.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Medicine and Surgery
Annals of Medicine and Surgery MEDICINE, GENERAL & INTERNAL-
自引率
5.90%
发文量
1665
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信